MVA.HIVconsv is in Phase 2 development as a therapeutic vaccine. (MVA.HIVconsv has also been studied for HIV prevention.)
(Compound details obtained from Treatment Action Group website1 and ClinicalTrials.gov2)
What is MVA.HIVconsv?
MVA.HIVconsv is an investigationalthat is being studied as a possible strategy to treat people living with HIV.1 MVA.HIVconsv belongs to a group of HIV vaccines called .
How do therapeutic HIV vaccines work?
A What is a Therapeutic HIV Vaccine? fact sheet.is a type of vaccine that’s designed to improve the body’s to HIV in a person living with HIV.3 Therapeutic vaccines may be able to reduce the amount of HIV in the body and help keep HIV at undetectable levels without the need for the regular use of (ART).4 To learn more, read the HIVinfo
There are several types of therapeutic vaccines that are currently being studied to treat HIV. MVA.HIVconsv belongs to a group of vaccines called viralvaccines.1 This type of vaccine delivers pieces of HIV’s DNA into the body’s cells. The body then uses this genetic information to produce an response that can fight the .5
In addition to being studied as a therapeutic HIV vaccine, MVA.HIVconsv has also been investigated to see if it can prevent HIVin people who do not have the virus.2,6,7 This record focuses on the study of MVA.HIVconsv as a therapeutic vaccine.
Select clinical trials of MVA.HIVconsv
- The purpose of the BCN01 study was to (1) evaluate the safety of both the MVA.HIVconsv vaccine and another investigational therapeutic HIV vaccine called ChAdV63.HIVconsv, and (2) investigate whether these vaccines could produce an immune response in people with recently diagnosed HIV infection who had on ART.
- The purpose of the BCN02-Romi study was to evaluate booster doses of MVA.HIVconsv in participants who had completed the BCN01 trial. MVA.HIVconsv was administered in combination with an investigational romidepsin. The study looked at whether this combination of treatments could reduce the size of the and control during an of ART.8,9 called
Selected Study Results: Results from the BCN01 trial published in EClinicalMedicine (2019) showed that the ChAdV63.HIVconsv and MVA.HIVconsv vaccines were safe, with most side effects being mild or moderate in severity. The vaccine regimen demonstrated strong HIV-specific and refocused immune cell responses against highly conserved regions of HIV. (Highly conserved regions of HIV are parts of the virus that change little across most strains.)10 BCN02 trial results published in Frontiers in Immunology (2020) showed that the administration of MVA.HIVconsv booster doses and romidepsin was generally safe; however, one participant experienced a serious side effect that was possibly related to romidepsin. The combined intervention resulted in only a modest reduction in the size of the latent HIV reservoir.11
Study Names: RIVER; NCT02336074
Status: This study is ongoing, but not recruiting participants.
Location: United Kingdom
Purpose: The purpose of this study is to determine whether using a combination of ART, the ChAdV63.HIVconsv and MVA.HIVconsv vaccines, and the investigational latency-reversing agent vorinostat can lead to a greater reduction in the size of the latent HIV reservoir than using ART alone.12
Selected Study Results: Results presented at AIDS 2018 and published in Lancet (2020) showed that the of ART plus the ChAdV63.HIVconsv and MVA.HIVconsv vaccines plus vorinostat produced no significant benefit in reducing the latent HIV reservoir as compared to ART alone.13,14
For more details on the studies listed above, see the Health Professional version of this drug summary.
A (HIV-CORE 001; NCT01024842) of MVA.HIVconsv in adults on ART who were virologically suppressed was also completed. This study looked at the safety of MVA.HIVconsv, its ability to produce an immune response in the body, and its ability to reduce the size of the latent HIV reservoir.15,16
What side effects might MVA.HIVconsv cause?
One goal of HIV research is to identify new drugs that have fewer side effects. The following side effects were observed in some of the studies of MVA.HIVconsv listed above.BCN01 (NCT01712425); BCN02-Romi (NCT02616874):
In the BCN01 study, the majority of participants experienced side effects, which ranged from mild to moderate in intensity. Most of the side effects related to vaccination were temporary and went away within 3 days. Pain at or near the injection site was more commonly reported with MVA.HIVconsv than with ChAdV63HIVconsv. The most common side effect after vaccination was a general feeling of discomfort or illness.17
The BCN02-Romi study enrolled a subset of participants who had completed the BCN01 study and evaluated additional doses of MVA.HIVconsv along with romidepsin. The most common side effects related to MVA.HIVconsv were injection site pain and flu-like symptoms (fatigue, headache, muscle pain, and/or low-grade fever). One participant experienced a serious side effect that was possibly related to romidepsin.9,11RIVER (NCT02336074):
In this Phase 2 study, 97% of participants who received ART along with ChAdV63.HIVconsv, MVA.HIVconsv, and vorinostat experienced side effects. Seventy percent of these side effects were mild, 23% were moderate, and 3% were severe in intensity. In the group that only received ART, 73% of participants experienced a side effect, of which 33% were mild, 20% were moderate, and 20% were severe. No serious side effects related to the study vaccines were reported.12,13,18
Because MVA.HIVconsv is still being studied, information on possible side effects of the vaccine is not complete. As testing of MVA.HIVconsv continues, additional information on possible side effects will be gathered.
Where can I get more information about clinical trials studying MVA.HIVconsv?
More information about MVA.HIVconsv-related research studies is available from.
Some clinical trials may be looking for volunteer participants. Your health care provider can help you decide whether participating in a NIH Clinical Research Trials and You.is right for you. For more information, visit
- Treatment Action Group website. Research toward a cure trials. https://www.treatmentactiongroup.org/cure/trials/. Accessed March 1, 2022
- University of Oxford. A Phase I study to evaluate the safety and immunogenicity of simultaneous prime-boost immunisations with candidate HCV and HIV-1 vaccines, AdCh3NSmut1 / ChAdV63.HIVconsv and MVA-NSmut / MVA.HIVconsv, in healthy volunteers. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered November 6, 2014. NLM Identifier: NCT02362217. https://clinicaltrials.gov/ct2/show/NCT02362217. Accessed March 1, 2022
- The History of Vaccines website. The development of HIV vaccines. https://www.historyofvaccines.org/content/articles/development-hiv-vaccines. Accessed March 1, 2022
- Graziani GM, Angel JB. Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. J Int AIDS Soc. 2015;18(1):20497.
- HIV Vaccine Trials Network website. Types of vaccines. https://www.hvtn.org/hiv-study-basics/key-hiv-vaccine-topics/types-of-vaccines.html. Accessed March 1, 2022
- University of Oxford. A randomized single-blind placebo-controlled study to evaluate the safety and immunogenicity of three candidate HIV-1 vaccines, pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv, administered in combination to healthy HIV 1 uninfected adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered June 24, 2010. NLM Identifier: NCT01151319. https://clinicaltrials.gov/ct2/show/NCT01151319. Accessed March 1, 2022
- University College, London. A randomised double-blind, placebo-controlled Phase I/IIa trial to investigate the effect of depletion of serum amyloid P component (SAP) on the immune response to DNA vaccination in healthy male volunteers. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered April 29, 2013. NLM Identifier: NCT02425241. https://clinicaltrials.gov/ct2/show/NCT02425241. Accessed March 1, 2022
- IrsiCaixa. Safety and immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv candidate HIV-1 vaccines in recently HIV-1 infected individuals with early viral suppression after initiation of antiretroviral therapy (HAART). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered October 4, 2012. NLM Identifier: NCT01712425. https://clinicaltrials.gov/ct2/show/NCT01712425. Accessed March 1, 2022
- IrsiCaixa. An open label Phase I trial to evaluate the safety and effect of HIVconsv vaccines in combination with histone deacetylase inhibitor romidepsin on the viral rebound kinetic after treatment interruption in early treated HIV-1 infected individuals (BCN02-Romi). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered November 9, 2015. NLM Identifier: NCT02616874. https://clinicaltrials.gov/ct2/show/NCT02616874. Accessed March 1, 2022
- Mothe B, Manzardo C, Sanchez-Bernabeu A, et al. Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study). EClinicalMedicine. 2019;11:65-80. doi:10.1016/j.eclinm.2019.05.009
- Mothe B, Rosás-Umbert M, Coll P, et al. HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: safety, immunogenicity and effect on the viral reservoir (Study BCN02). Front Immunol. 2020;11:823. doi:10.3389/fimmu.2020.00823
- Imperial College London. Research in viral eradication of HIV reservoirs. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on October 23, 2014. NLM Identifiier: NCT02336074. https://www.clinicaltrials.gov/ct2/show/NCT02336074. Accessed March 1, 2022
- Fidler S. RIVER research in viral eradication of HIV reservoirs: a two-arm (proof of concept) randomised Phase II trial vorinostat plus a prime boost vaccine. Slides presented at: International AIDS Conference; July 23-27, 2018; Amsterdam, Netherlands. https://programme.aids2018.org/PAGMaterial/PPT/6106_3214/RIVER presentation at IAS 24.7.2018 final draft.pptx Accessed March 1, 2022
- Fidler S, Stöhr W, Pace M, et al. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. Lancet Lond Engl. 2020;395(10227):888-898. doi:10.1016/S0140-6736(19)32990-3
- University of Oxford. HIV-CORE 001 - a randomised placebo-controlled study to evaluate the safety and immunogenicity of a candidate HIV-1 vaccine, MVA.HIVconsv, delivered by intramuscular needle injection to HIV-1 seropositive adult subjects receiving antiretroviral therapy (ART). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered December 1, 2009. NLM Identifier: NCT01024842. https://clinicaltrials.gov/ct2/show/NCT01024842. Accessed March 1, 2022
- Hancock G, Morón-López S, Kopycinski J, et al. Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects. J Int AIDS Soc. 2017;20(1). doi:10.7448/IAS.20.1.21171
- Mothe B, Manzardo C, Coll P, et al. Shaping CTL immunodominance with conserved HIV vaccines after early treatment (BCN01). Poster presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 22-25, 2016; Boston, MA. Poster 320. https://2jg4quetidw2blbbq2ixwziw-wpengine.netdna-ssl.com/wp-content/uploads/sites/2/posters/2016/320.pdf. Accessed March 1, 2022
- Fidler S, Stohr W, Pace M, et al. A randomised controlled trial comparing the impact of antiretroviral therapy (ART) with a “Kick-and-Kill” approach to ART alone on HIV reservoirs in individuals with primary HIV infection (PHI); RIVER trial. Abstract presented at: International AIDS Conference; July 23-27, 2018; Amsterdam, Netherlands. Abstract TUAA0202LB. http://programme.aids2018.org/Abstract/Abstract/12977. Accessed March 1, 2022
Last Reviewed: March 1, 2022